Focused on
Finding a
Cure
The Syncromune Team is dedicated to developing combination multi-target immunotherapies to fight metastatic solid tumors in a new way
Pioneers in Combination Multi-Target Immunotherapy
Syncromune is a privately held, clinical-stage biopharmaceutical company dedicated to the development of an in situ platform therapy optimized for metastatic solid tumor cancers that aims to achieve high response rates with potentially improved survival. The company is currently developing SYNC-T, a novel and personalized therapy that combines a multi-target biologic drug and oncolysis. SYNC-T is designed to target multiple mechanisms of cancer, promoting in situ immune activation while battling immunosuppression. The goal is to activate T cells, enabling the immune system to recognize and attack cancer throughout the body. The first two candidates, SV-101 and SV-102, are currently in Phase 1 trials.
Our Mission
We aspire to develop a completely in situ immunotherapy platform technology optimized for solid tumor cancers that achieves high response rates with potentially curative efficacy
Our Values
C
Caring
Every member of the Syncromune team is inspired by the opportunities to change the lives of patients and their families and bring hope to those who have exhausted their treatment options.
U
Unique
At Syncromune we are doing things that have never been done and developing a disruptive technology that is paving the way for a whole new approach to treating metastatic solid tumor cancers.
R
Relentless
We are focused every day on our pursuit of developing a cure for metastatic solid tumor cancers. Our team works relentlessly with the goal of helping patients in need.
E
Ethical
Syncromune is committed to maintaining high standards of personal conduct, practicing honesty in all our professional relationships and endeavors. We believe in being truthful in our actions and words.
EXECUTIVE LEADERSHIP
CHARLES LINK, MD
EXECUTIVE CHAIRMAN
EAMONN HOBBS
PRESIDENT & CEO
JEFFREY KRAWS
CHIEF FINANCIAL OFFICER
JONATHAN LEWIS, MD, PHD
CHIEF MEDICAL OFFICER
GREGORY CHAMPION
CHIEF LEGAL OFFICER
AGUSTIN GAGO
CHIEF OPERATING OFFICER
MARIO MAUTINO, PHD
CHIEF SCIENTIFIC OFFICER
BOARD OF DIRECTORS
CHARLES LINK, MD
EXECUTIVE CHAIRMAN
EAMONN HOBBS
PRESIDENT & CEO
DOUGLAS WATSON
LEAD INDEPENDENT DIRECTOR
JEFFREY CLELAND, PHD
INDEPENDENT DIRECTOR
SCIENTIFIC ADVISORY BOARD
JAMES ARMITAGE, M.D.
- The Joe Shapiro Professor of Medicine Professor, Division of Oncology & Hematology, UNMC
- Past President of ASTCT and ASCO
GEORGE C. PRENDERGAST, PH.D.
- President and CEO of the Lankenau Institute for Medical Research (LIMR)
- Former Editor-in-Chief of Cancer Research
RICHARD HARRIS, M.D.
- CEO of UroPartners
- Past President of Large Urology Group Practice Association (LUGPA) BOD
THOMAS RAFFIN, M.D.
- Stanford University School of Medicine Colleen and Robert Haas Professor Emeritus of Medicine and Biomedical Ethics
- Former Chief of Pulmonary and Critical Care Medicine
ALAN EPSTEIN, PH.D.
- University of Southern California
- Professor, Keck School of Medicine
DAVID VAUGHAN, M.D.
- Former Chairman of Department of Urology at Florida Hospital & Winter Park Hospital
- Former Partner of Orlando Urology Associates
SUMING WANG, M.D., PH.D.
- Founded Shanghai Mingda Biotech, an immune therapy company in 2014
- Former CEO of Shanghai East International Medical Center
- Vice President of NewLink Genetics from 1999-2008
YOUSEF ZAKHARIA, M.D.
- Clinical Associate Professor of Medicine, University of Iowa
- Director Phase I Program, Co-Leader Genitourinary Oncology Program, University of Iowa
Disclaimers: The content on this website is intended for healthcare professionals. The compounds and their uses mentioned on this website are investigational and have not been determined safe and effective by the relevant regulatory authorities, including the US Food and Drug Administration or other applicable agencies in other countries.
